Happy Friday! No excuses for last Friday 😡.
Last week, I was honored to be on a panel hosted by the awesome Ritesh Patel, CDO at Ogilvy Health. The topic was “Healthcare 2021, What does this year have in store for us”. It was a 90 min discussion and hundreds of attendees hung around with us (Chandana Fitzgerald, Cris Deluca, Emmanuel Fombu) discussing our predictions.
Guess what… the future of pharma came up and I had to jump in 😂 - especially as this topic is one of the last chapters aka “The Conclusion”. My somewhat controversial question and probably highly unexpected (for those who know me) was: “Does pharma actually need to change"?”
👇🏼👇🏼👇🏼
The margins are healthy for the industry
New biological modalities are here + continued pipeline of Biotechs
Digital Health as a whole does not generate even close to the revenues of a successful brand (take Teladoc that acquired Livongo for ~$18B = their combined expected 2020 revenues are ~$1.1B - a fraction of one blockbuster brand)
Digital Therapeutics is still a relatively wild, wild west and continuing to (re)shape - 🎧 to my podcast on this topic where I partnered up with Brian Dolan as my journalistic partner.
ok, ok so I actually do think that pharma needs to change.. and I will save the rest of my conclusion for the book itself and depending on when I start the podcast, I may or may not disclose more in these updates. I know, you are probably sitting on the edge of your seat…
I am sure that Paul Simms will have a lot to say on this topic
Till Next Time,